Preliminary evidence of FABP2 A54T polymorphism associated with reduced risk of type 2 diabetes and obesity in women from a German cohort

被引:27
作者
Fisher, E.
Li, Y.
Burwinkel, B.
Kuehr, V.
Hoffmann, K.
Moehlig, M.
Spranger, J.
Pfeiffer, A.
Boeing, H.
Schrezenmeir, J.
Doering, F.
机构
[1] German Inst Human Nutr Potsdam Rehbruck, Dept Epidemiol, D-14558 Nuthetal, Germany
[2] Univ Kiel, Res Grp Mol Nutr, Kiel, Germany
[3] German Canc Res Ctr, Div Mol Genet Epidemiol, D-6900 Heidelberg, Germany
[4] Univ Hohenheim, Inst Plant Breeding, D-7000 Stuttgart, Germany
[5] German Inst Human Nutr Potsdam Rehbrucke, Dept Clin Nutr, D-14558 Nuthetal, Germany
[6] Fed Res Ctr Nutr & Food, Inst Physiol & Biochem Nutr, Kiel, Germany
关键词
intestinal fatty acid binding protein; A54T polymorphism; type; 2; diabetes; sexual dimorphism;
D O I
10.1055/s-2006-925400
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The T54 variant of the FABP2 gene has shown an association with the insulin resistance syndrome in some, but not all, studies. Here, we tested the hypothesis that the association between FABP2 A54T genotype and type 2 diabetes (T2DM) is confounded by body mass index (BMI) and is different between the two genders. 192 incident cases of T2DM and 384 sex- and age-matched controls were taken from the EPIC-Potsdam study cohort. Logistic regression analyses revealed that BMI was a strong confounder for diabetes risk association among women. When adjusted for BMI, the homozygous T54 variant was significantly associated with reduced risk of T2DM in women (OR = 0.24, 95%CI: 0.07-0.82), but not in men in the co-dominant inheritance model. Accordingly, HbA(1c) values were significantly lower in women carrying two T54 alleles with BMI regarded as covariate. While accounting for potentially confounding effects, linear trends of increased BMI and leptin values were observed in women according to the presence of T54 alleles. The interaction term (p = 0.04) of continuous BMI and T54-coding genotypes suggested that the T54 variant is an effect-modifier for BMI in females. We conclude that the T54 allele of FABP2 A54T is associated both with higher BMI and reduced risk of T2DM in women from the German EPIC-Potsdam study.
引用
收藏
页码:341 / 345
页数:5
相关论文
共 23 条
[1]  
Ågren JJ, 2001, AM J CLIN NUTR, V73, P31
[2]   Intestinal FABP2 A54T polymorphism:: Association with insulin resistance and obesity in women [J].
Albala, C ;
Santos, JL ;
Cifuentes, M ;
Villarroel, AC ;
Lera, L ;
Liberman, C ;
Angel, B ;
Pérez-Bravo, F .
OBESITY RESEARCH, 2004, 12 (02) :340-345
[3]   AN AMINO-ACID SUBSTITUTION IN THE HUMAN INTESTINAL FATTY-ACID-BINDING PROTEIN IS ASSOCIATED WITH INCREASED FATTY-ACID-BINDING, INCREASED FAT OXIDATION, AND INSULIN-RESISTANCE [J].
BAIER, LJ ;
SACCHETTINI, JC ;
KNOWLER, WC ;
EADS, J ;
PAOLISSO, G ;
TATARANNI, PA ;
MOCHIZUKI, H ;
BENNETT, PH ;
BOGARDUS, C ;
PROCHAZKA, M .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :1281-1287
[4]   A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells [J].
Baier, LJ ;
Bogardus, C ;
Sacchettini, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (18) :10892-10896
[5]   Follow-up procedures in EPIC-Germany - Data quality aspects [J].
Bergmann, MM ;
Bussas, U ;
Boeing, H .
ANNALS OF NUTRITION AND METABOLISM, 1999, 43 (04) :225-234
[6]   Recruitment procedures of EPIC-Germany [J].
Boeing, H ;
Korfmann, A ;
Bergmann, MM .
ANNALS OF NUTRITION AND METABOLISM, 1999, 43 (04) :205-215
[7]   Obesity, Type II diabetes and the Ala54Thr polymorphism of fatty acid binding protein 2 in the Tongan population [J].
Duarte, NL ;
Colagiuri, S ;
Palu, T ;
Wang, XL ;
Wilcken, DEL .
MOLECULAR GENETICS AND METABOLISM, 2003, 79 (03) :183-188
[8]  
Endo K, 2001, J Atheroscler Thromb, V8, P80
[9]  
Erkkilä AT, 2002, NUTR METAB CARDIOVAS, V12, P53
[10]   Association of the ala54-thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study [J].
Galluzzi, JR ;
Cupples, LA ;
Meigs, JB ;
Wilson, PWF ;
Schaefer, EJ ;
Ordovas, JM .
DIABETES CARE, 2001, 24 (07) :1161-1166